Key result
During STEMI, platelet S100A8 and S100A9 levels were significantly elevated compared to stable coronary artery disease (fold change 2.00 and 2.28, respectively; FDR ≤0.05).
Why the study?
Platelets are central to acute MI, but how the platelet proteome is altered during MI is unknown.
Observational (n=393)
Effect estimate: FC 2.00 for S100A8, FC 2.28 for S100A9
p-value: p=FDR 0.05 for S100A8, FDR 0.005 for S100A9
Leukocyte-to-platelet transfer of S100A8/A9 occurs during STEMI and is inversely associated with platelet reactivity, highlighting neutrophils as potential modifiers for thrombotic therapies.
S100A8/A9 may modulate platelet reactivity in STEMI; hypothesis-generating for neutrophil-targeted therapies and should not yet change practice.
Objective: Platelets are central to acute myocardial infarction (MI). How the platelet proteome is altered during MI is unknown. We sought to describe changes in the platelet proteome during MI and identify corresponding functional consequences. Approach and Results: Platelets from patients experiencing ST-segment–elevation MI (STEMI) before and 3 days after treatment (n=30) and matched patients with severe stable coronary artery disease before and 3 days after coronary artery bypass grafting (n=25) underwent quantitative proteomic analysis. Elevations in the proteins S100A8 and S100A9 were detected at the time of STEMI compared with stable coronary artery disease (S100A8: FC, 2.00; false discovery rate, 0.05; S100A9: FC, 2.28; false discovery rate, 0.005). During STEMI, only S100A8 mRNA and protein levels were correlated in platelets ( R =0.46, P =0.012). To determine whether de novo protein synthesis occurs, activated platelets were incubated with 13C-labeled amino acids for 24 hours and analyzed by mass spectrometry. No incorporation was confidently detected. Platelet S100A8 and S100A9 was strongly correlated with neutrophil abundance at the time of STEMI. When isolated platelets and neutrophils were coincubated under quiescent and activated conditions, release of S100A8 from neutrophils resulted in uptake of S100A8 by platelets. Neutrophils released S100A8/A9 as free heterodimer, rather than in vesicles or extracellular traps. In the community-based Bruneck study (n=338), plasma S100A8/A9 was inversely associated with platelet reactivity—an effect abrogated by aspirin. Conclusions: Leukocyte-to-platelet protein transfer may occur in a thromboinflammatory environment such as STEMI. Plasma S100A8/A9 was negatively associated with platelet reactivity. These findings highlight neutrophils as potential modifiers for thrombotic therapies in coronary artery disease.
No takes yet. Share an insight, caveat, or question.
A 2021 study conducted an observational in Acute Myocardial Infarction (n=393). STEMI vs. Stable coronary artery disease was evaluated on Elevations in the proteins S100A8 and S100A9 (FC 2.00 for S100A8, FC 2.28 for S100A9, p=FDR 0.05 for S100A8, FDR 0.005 for S100A9). During STEMI, platelet S100A8 and S100A9 levels were significantly elevated compared to stable coronary artery disease (fold change 2.00 and 2.28, respectively; FDR ≤0.05).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: